Skip to content
← All treatment topics

TREATMENT READING

Childhood Thyroid Cancer

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

31 sections
  1. Treatment of Papillary and Follicular Thyroid Carcinoma
  2. Preoperative evaluation
  3. Surgery
  4. Thyroidectomy
  5. Central neck dissection
  6. Lateral neck dissection
  7. Classification and risk assignment
  8. Postoperative staging and long-term surveillance
  9. ATA pediatric low risk
  10. ATA pediatric intermediate risk
  11. ATA pediatric high risk
  12. Radioactive iodine ablation (RAI)
  13. Treatment of Recurrent Papillary and Follicular Thyroid Carcinoma
  14. RAI with 131I
  15. Tyrosine kinase inhibitors (TKIs)
  16. Treatment options under clinical evaluation for recurrent papillary and follicular thyroid carcinoma
  17. Treatment of Medullary Thyroid Carcinoma
  18. Surgery
  19. Tyrosine kinase inhibitor (TKI) therapy
  20. Treatment options under clinical evaluation for medullary thyroid carcinoma
  21. Special Considerations for the Treatment of Children With Cancer
  22. Types of treatment for childhood thyroid cancer
  23. Who treats children with thyroid cancer?
  24. Surgery
  25. Radioactive iodine therapy
  26. Targeted therapy
  27. Clinical trials
  28. Treatment of newly diagnosed childhood papillary and follicular thyroid cancer
  29. Treatment of newly diagnosed childhood medullary thyroid cancer
  30. Treatment of progressive or recurrent childhood thyroid cancer
  31. Side effects and late effects of treatment

Health professional · Differentiated Thyroid Cancer (Papillary/Follicular)

Treatment of Papillary and Follicular Thyroid Carcinoma

Source: Childhood Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

Treatment options for papillary and follicular (differentiated) thyroid carcinoma include the following:

Surgery.

Sources: Surgery

Radioactive iodine ablation (RAI).

Sources: Radioactive iodine ablation (RAI)

Because differentiated thyroid cancer is rare in children, centralization of care to expert centers is highly encouraged.[6,9,24]

Sources: 6 · 9 · 24

In 2015, the American Thyroid Association (ATA) Task Force on Pediatric Thyroid Cancer published guidelines for the management of thyroid nodules and differentiated thyroid cancer in children and adolescents. These guidelines are based on scientific evidence and expert panel opinion, with a careful assessment of the level of evidence.[9] In 2020 and 2022, the Cancer Committee of the American Pediatric Surgery Association and the European Thyroid Association (ETA) reviewed and expanded the ATA guidelines by incorporating more recent evidence.[24] The following sections of this summary provide an overview of the ATA guidelines and the proposed revisions, which are presented here without a specific endorsement by the National Cancer Institute (NCI).

Sources: 9 · 24

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional · Differentiated Thyroid Cancer (Papillary/Follicular) / Treatment of Papillary and Follicular Thyroid Carcinoma

Preoperative evaluation

Source: Childhood Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

Preoperative evaluation factors to consider include the following:

Neck palpation and a comprehensive ultrasonography of all regions of the neck using a high-resolution probe and Doppler technique should be obtained by an experienced ultrasonographer. A complete ultrasonography examination should be performed before surgery.[6,9]

Sources: 6 · 9

The addition of cross-sectional imaging (contrast-enhanced computed tomography [CT] or magnetic resonance imaging) should be considered when there is concern about invasion of the aerodigestive tract. Importantly, if iodinated contrast agents are used, further evaluation and treatment with radioactive iodine may need to be delayed for 2 to 3 months until total body iodine burden decreases.[9]

Sources: 9

Chest imaging (x-ray or CT) may be considered for patients with substantial cervical lymph node disease.[9]

Sources: 9

Thyroid nuclear scintigraphy should be pursued only if the patient presents with suppressed thyroid-stimulating hormone (TSH).[9]

Sources: 9

The routine use of bone scan or fluorine F 18-fludeoxyglucose positron emission tomography (PET) is not recommended.[9]

Sources: 9

Further genetic or imaging diagnostics should be considered in cases of suspected familiar or extensive disease.[6]

Sources: 6

Health professional · Differentiated Thyroid Cancer (Papillary/Follicular) / Treatment of Papillary and Follicular Thyroid Carcinoma

Surgery

Source: Childhood Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

Total thyroidectomy is the cornerstone of the management of differentiated thyroid carcinoma. Pediatric thyroid surgery is ideally completed by a surgeon who has experience performing endocrine procedures in children and in a hospital with the full spectrum of pediatric specialty care. The ATA recommends that the thyroidectomy be performed by an experienced thyroid surgeon (>30 cases/year) or as a multidisciplinary approach between a pediatric surgeon and an adult endocrine or head and neck surgeon.[6,9]

Sources: 6 · 9

Health professional · Differentiated Thyroid Cancer (Papillary/Follicular) / Treatment of Papillary and Follicular Thyroid Carcinoma / Surgery

Thyroidectomy

Source: Childhood Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

For patients with papillary or follicular carcinoma, total thyroidectomy is the recommended treatment. The ATA expert panel recommendation is based on data showing an increased incidence of bilateral (30%) and multifocal (65%) disease.[6,9]

Sources: 6 · 9

In patients with a small unilateral tumor confined to the gland, a near-total thyroidectomy—in which a small amount of thyroid tissue (<1%–2%) is left in place at the entry point of the recurrent laryngeal nerve or superior parathyroid glands—might be considered to decrease permanent damage to those structures.[40]

Sources: 40

A retrospective analysis identified factors associated with bilateral thyroid involvement in 115 pediatric patients with well-differentiated thyroid cancer.[41] Bilateral disease was present in 47 of 115 participants (41%). In multivariable analysis, only multifocality in the primary lobe was independently associated with bilateral disease (OR, 7.61; 95% CI, 2.44–23.8; P < .001). Among clinically node-negative patients with papillary carcinoma who did not have tumor multifocality in the primary lobe, bilateral disease was present in 5 of 32 patients (16%). The authors concluded that in children with differentiated thyroid cancer, tumor multifocality in the primary lobe is associated with bilateral disease, and they recommended prompt consideration of complete thyroidectomy after initial lobectomy.

Sources: 41

Another multicenter retrospective analysis evaluated the prevalence of and risk factors for multifocal disease in 212 pediatric patients with papillary thyroid carcinoma.[42] The mean age at diagnosis was 14.1 years, and 23 patients were aged 10 years or younger. A total of 173 patients (82%) were female. Any amount of multifocal disease was present in 98 cases (46%), with bilateral multifocal disease present in 73 cases (34%). Predictors for multifocal and bilateral multifocal disease included age 10 years or younger, T3 tumor stage, and N1b nodal stage. The authors concluded that these risk factors and the high prevalence of multifocal disease should be considered when assessing the risks and benefits of surgical management options in pediatric patients with papillary thyroid carcinoma.

Sources: 42

Thyroid resections that are less than a total thyroidectomy are associated with up to tenfold greater recurrence rates. Total thyroidectomy also optimizes the use of radioactive iodine for imaging and treatment.

Health professional · Differentiated Thyroid Cancer (Papillary/Follicular) / Treatment of Papillary and Follicular Thyroid Carcinoma / Surgery

Central neck dissection

Source: Childhood Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

A therapeutic central neck lymph node dissection (level VI nodes) should be done in the presence of clinical evidence of central or lateral neck metastases.[13]

Sources: 13

For patients without clinical evidence of gross extrathyroidal invasion or locoregional metastasis, a prophylactic central neck dissection may be considered based on tumor focality and primary tumor size. However, because of the increased morbidity associated with central lymph node dissection, it is important to consider the risks and benefits of the extent of dissection on a case-by-case basis.[43]

Sources: 43

Health professional · Differentiated Thyroid Cancer (Papillary/Follicular) / Treatment of Papillary and Follicular Thyroid Carcinoma / Surgery

Lateral neck dissection

Source: Childhood Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

Modified radical neck dissection is reserved for biopsy-proven metastatic disease in the lateral compartment (levels II, III, IV, and V). Cytological confirmation of metastatic disease to lymph nodes in the lateral neck is recommended before surgery.

Routine prophylactic lateral neck dissection is not recommended.

Health professional · Differentiated Thyroid Cancer (Papillary/Follicular) / Treatment of Papillary and Follicular Thyroid Carcinoma

Classification and risk assignment

Source: Childhood Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

Despite the limited data in pediatrics, the ATA Task Force recommends the use of the tumor-node-metastasis (TNM) classification system to categorize patients into one of three risk groups.[9] This categorization strategy is meant to define the risk of persistent cervical disease and help determine which patients should undergo postoperative staging for the presence of distant metastasis.

Sources: 9

ATA pediatric low risk: Disease confined to the thyroid with N0 or NX disease or patients with incidental N1a (microscopic metastasis to a small number of central neck nodes). These patients are at lowest risk of distant disease but may still be at risk of residual cervical disease, especially if the initial surgery did not include central neck dissection.

ATA pediatric intermediate risk: Extensive N1a or minimal N1b disease. These patients are at low risk of distant metastasis but are at an increased risk of incomplete lymph node resection and persistent cervical disease.

ATA pediatric high risk: Regionally extensive disease (N1b) or locally invasive disease (T4), with or without distant metastasis. Patients in this group are at the highest risk of incomplete resection, persistent disease, and distant metastasis.

For more information about the TNM system, see the Stage Information for Thyroid Cancer section in Thyroid Cancer Treatment.

Sources: Stage Information for Thyroid Cancer

Health professional · Differentiated Thyroid Cancer (Papillary/Follicular) / Treatment of Papillary and Follicular Thyroid Carcinoma

Postoperative staging and long-term surveillance

Source: Childhood Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

After surgical resection, disease is staged based on the operative findings to identify patients with persistent disease and those at intermediate or high risk of recurrence. Initial staging should be performed within 12 weeks after surgery to assess for evidence of persistent locoregional disease and to identify patients who are likely to benefit from additional therapy with 131I. The ATA pediatric risk level helps determine the extent of postoperative testing.[9] The standard imaging study for the follow-up of patients who have been treated for differentiated thyroid carcinoma is neck ultrasonography. It should be performed by a professional with experience using this procedure in children. The sensitivity and specificity of neck ultrasonography for recurrent differentiated thyroid carcinoma in follow-up for children who have been treated with total thyroidectomy are 85.7% and 89.4%, respectively.[6]

Sources: 9 · 6

Health professional · Differentiated Thyroid Cancer (Papillary/Follicular) / Treatment of Papillary and Follicular Thyroid Carcinoma / Postoperative staging and long-term surveillance

ATA pediatric low risk

Source: Childhood Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

Initial postoperative staging includes a TSH-suppressed thyroglobulin. A diagnostic iodine I 123 (123I) scan is not required.

TSH suppression should be targeted to serum levels of 0.5 to 1.0 mIU/L.

In patients with no evidence of disease, surveillance should include ultrasonography at 6 months postoperatively and then annually for 5 years, as well as TSH-suppressed thyroglobulin levels every 3 to 6 months for 2 years and then annually.

In children with positive thyroglobulin antibodies (common in patients with Hashimoto thyroiditis), trending thyroglobulin is less reliable, and a diagnostic 123I scan may be required.

Health professional · Differentiated Thyroid Cancer (Papillary/Follicular) / Treatment of Papillary and Follicular Thyroid Carcinoma / Postoperative staging and long-term surveillance

ATA pediatric intermediate risk

Source: Childhood Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

Initial postoperative staging includes a TSH-stimulated thyroglobulin and diagnostic 123I whole-body scan for further stratification and determination with 131I.

TSH suppression should be targeted to serum levels of 0.1 to 0.5 mIU/L.

In patients with no evidence of disease, surveillance should include ultrasonography at 6 months postoperatively and then every 6 to 12 months for 5 years (and then less frequently), as well as thyroglobulin levels (on hormone replacement therapy) every 3 to 6 months for 3 years and then annually.

TSH-stimulated thyroglobulin and diagnostic 123I scan should be considered in 1 to 2 years for patients treated with 131I.

Health professional · Differentiated Thyroid Cancer (Papillary/Follicular) / Treatment of Papillary and Follicular Thyroid Carcinoma / Postoperative staging and long-term surveillance

ATA pediatric high risk

Source: Childhood Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

Initial postoperative staging includes a TSH-stimulated thyroglobulin and diagnostic 123I whole-body scan for further stratification and determination with 131I.

TSH suppression should be targeted to serum levels of less than 0.1 mIU/L.

In patients with no evidence of disease, surveillance should include ultrasonography at 6 months postoperatively and then every 6 to 12 months for 5 years (and then less frequently), as well as thyroglobulin levels (on hormone replacement therapy) every 3 to 6 months for 3 years and then annually.

TSH-stimulated thyroglobulin and, possibly, a diagnostic 123I scan in 1 to 2 years in patients treated with 131I.

For patients with antithyroglobulin antibodies, deferred postoperative staging to allow time for antibody clearance, except in patients with T4 or M1 disease.

Health professional · Differentiated Thyroid Cancer (Papillary/Follicular) / Treatment of Papillary and Follicular Thyroid Carcinoma

Radioactive iodine ablation (RAI)

Source: Childhood Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

The goal of 131I therapy is to decrease recurrence and mortality by eliminating iodine-avid disease.[6,9]

Sources: 6 · 9

The ATA Task Force recommends the use of 131I for the treatment of iodine-avid, persistent locoregional, or nodal disease that cannot be resected, and for known or presumed iodine-avid distant metastases. For patients with persistent disease after administration of 131I, the decision to pursue additional 131I therapy should be individualized based on clinical data and previous response. For patients without lymph node or distant metastases, there is no evidence that 131I can improve survival or reduce recurrence rates.[6]

Sources: 6

To facilitate 131I uptake by residual iodine-avid disease, the TSH level should be above 30 mIU/L. This level can be achieved by withdrawing levothyroxine for at least 14 days. A low-iodine diet should also be followed for 2 weeks before therapy. RAI should be deferred for 2 to 3 months after exposure to iodinated CT contrast, and urine iodine excretion should be confirmed to be less than 75 µ/L. In patients who cannot mount an adequate TSH response or cannot tolerate profound hypothyroidism, recombinant human TSH may be used.

Therapeutic 131I administration is commonly based on either empiric dosing or whole-body dosimetry. Based on the lack of data comparing empiric treatment and treatment informed by dosimetry, the ATA Task Force was unable to recommend one specific approach. However, because of the differences in body size and iodine clearance in children compared with adults, all activities of 131I should be calculated by experts with experience in dosing children.

A posttreatment whole-body scan is recommended for all children 4 to 7 days after 131I therapy. The addition of single-photon emission CT with integrated conventional CT (SPECT/CT) may help to distinguish the anatomic location of focal uptake.While rare, late effects of 131I treatment include salivary gland dysfunction, bone marrow suppression, pulmonary fibrosis, and second malignancies.[44]

Sources: 44

Because response to 131I may be observed up to 15 to 18 months after therapy, long intervals of at least 12 months are suggested before re-treatment.[6]

Sources: 6

Evidence (RAI):

In a multicenter study of children and adolescents with differentiated thyroid carcinoma, 285 consecutive patients were treated with total thyroidectomy and RAI according to the ATA guidelines.[45]

Sources: 45

In a multicenter study of children and adolescents with differentiated thyroid carcinoma, 285 consecutive patients were treated with total thyroidectomy and RAI according to the ATA guidelines.[45]

87% of the patients had no evidence of active disease at a median follow-up of 133 months.

In a single-center study of ATA pediatric low-risk differentiated thyroid cancer diagnosed between 2010 and 2020, 95 patients underwent total thyroidectomy followed by 131I therapy in 53% of patients.[46]

Sources: 46

In a single-center study of ATA pediatric low-risk differentiated thyroid cancer diagnosed between 2010 and 2020, 95 patients underwent total thyroidectomy followed by 131I therapy in 53% of patients.[46]

There was no statistical difference in remission rates between patients treated with or without 131I therapy at 1 year (70% vs. 68.9%, respectively; P = .089) or last clinical evaluation (82% vs. 75.6%; P = .534).

Over the study period, use of 131I in the patient population declined steadily, as the 2015 ATA Pediatric Differentiated Thyroid Cancer Guidelines recommended withholding 131I therapy in patients with low-risk disease. Accordingly, patients who received 131I therapy had longer follow-up (median, 5.8 years) than those who did not receive 131I therapy (median, 3.6 years).

The ETA has proposed a simplified follow-up plan based on thyroglobulin levels and neck ultrasonography (see Figure 4).[6]

Sources: Figure 4 · 6

Health professional · Differentiated Thyroid Cancer (Papillary/Follicular)

Treatment of Recurrent Papillary and Follicular Thyroid Carcinoma

Source: Childhood Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

Despite having more advanced disease at presentation than adults, children with differentiated thyroid cancer generally have an excellent survival with relatively few side effects.[25,47,48] For this reason, treatment of persistent or recurrent disease should be individualized, and the potential risks and benefits of therapy should be carefully considered. For children with persistent but not rising thyroglobulin levels on TSH suppression, primary neck ultrasonography is recommended; if negative, 123I scanning may be considered under TSH stimulation. If no residual or recurrent disease is found, serum thyroglobulin and serum thyroglobulin antibodies must be measured every 3 to 6 months. Patients with small cervical foci (i.e., <1 cm) or patients with cervical disease that cannot be visualized with cross-sectional imaging may be considered for (repeat) therapeutic 131I. However, these patients may also be safely observed while maintaining TSH suppression. Macroscopic cervical disease should be removed surgically if it can be safely accomplished. Children with pulmonary metastases may continue to experience posttherapy targeted 131I effects for years, and an undetectable thyroglobulin level should not be the focus of treatment efforts. As many as one-third of patients exhibit persistent but stable disease following RAI. Therapy should be considered only in patients who show signs of progression.[9,24]

Sources: 25 · 47 · 48 · 9 · 24

Treatment options for recurrent papillary and follicular thyroid carcinoma include the following:

RAI with 131I.

Sources: RAI with 131I

Tyrosine kinase inhibitors (TKIs).

Sources: Tyrosine kinase inhibitors (TKIs)

Health professional · Differentiated Thyroid Cancer (Papillary/Follicular) / Treatment of Recurrent Papillary and Follicular Thyroid Carcinoma

RAI with 131I

Source: Childhood Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

RAI with 131I is usually effective after recurrence.[49]

Sources: 49

Health professional · Differentiated Thyroid Cancer (Papillary/Follicular) / Treatment of Recurrent Papillary and Follicular Thyroid Carcinoma

Tyrosine kinase inhibitors (TKIs)

Source: Childhood Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

For patients with 131I-refractory disease, molecularly targeted therapies using TKIs may provide alternative therapies.

TKIs with documented efficacy for the treatment of adults include the following:

Sorafenib. Sorafenib is a VEGFR, PDGFR, and RAS kinase inhibitor. In a randomized phase III trial, sorafenib improved PFS when compared with placebo (10.8 months vs. 5.8 months) in adult patients with radioactive iodine–refractory locally advanced or metastatic differentiated thyroid cancer.[50] The U.S. Food and Drug Administration (FDA) approved sorafenib in 2013 for the treatment of adults with late-stage, metastatic differentiated thyroid carcinoma. Pediatric-specific data are limited. However, in one case report, sorafenib produced a radiographic response in a patient aged 8 years with metastatic papillary thyroid carcinoma.[51]

Sources: 50 · 51

Lenvatinib. Lenvatinib is an oral VEGFR, FGFR, PDGFR, RET, and KIT inhibitor. In a phase III randomized study of adults with 131I-refractory differentiated thyroid cancer, lenvatinib was associated with a significant improvement in PFS and response rate when compared with a placebo.[52] The FDA approved lenvatinib in 2015 for the treatment of adults with progressive, radioactive iodine–refractory differentiated thyroid carcinoma.Three children with papillary thyroid carcinoma who were refractory to radioactive iodine had a clinical response to lenvatinib.[53]

Sources: 52 · 53

Vemurafenib and dabrafenib (BRAF inhibitors). An open-label, nonrandomized, phase II study of vemurafenib was conducted in adult patients with papillary thyroid carcinoma that was 131I-refractory, metastatic or unresectable, and BRAF V600E variant positive. No participant had been previously treated with a TKI. A response rate of 38.5% was documented.[54] For patients with metastatic or advanced BRAF V600E–altered anaplastic thyroid carcinoma, the combination of dabrafenib with the MEK inhibitor trametinib showed a response rate of 69%.[55]

Sources: 54 · 55

Larotrectinib and entrectinib (NTRK inhibitors). Larotrectinib has been used to treat patients with TRK fusion–positive thyroid carcinoma. In one study, all five patients with TRK fusion–positive thyroid carcinomas who received larotrectinib therapy achieved partial or complete responses.[56] Responses to entrectinib have also been reported.[57] The FDA approved larotrectinib and entrectinib for the treatment of adults and children (restricted to patients older than 12 years for entrectinib) with solid tumors that include all of the following characteristics:[58]

Sources: 56 · 57 · 58

Larotrectinib and entrectinib (NTRK inhibitors). Larotrectinib has been used to treat patients with TRK fusion–positive thyroid carcinoma. In one study, all five patients with TRK fusion–positive thyroid carcinomas who received larotrectinib therapy achieved partial or complete responses.[56] Responses to entrectinib have also been reported.[57] The FDA approved larotrectinib and entrectinib for the treatment of adults and children (restricted to patients older than 12 years for entrectinib) with solid tumors that include all of the following characteristics:[58]

Have an NTRK gene fusion without a known acquired resistance variant.

Are metastatic or for which surgical resection is likely to result in severe morbidity.

Have no satisfactory alternative treatments or that have progressed following treatment.

Selpercatinib (a RET inhibitor). In a phase I/II trial of selpercatinib therapy for patients (age range, 25–88 years) with RET-altered cancers, 19 patients with RET fusion–positive, previously treated thyroid cancers were enrolled.[59]

Sources: 59

Selpercatinib (a RET inhibitor). In a phase I/II trial of selpercatinib therapy for patients (age range, 25–88 years) with RET-altered cancers, 19 patients with RET fusion–positive, previously treated thyroid cancers were enrolled.[59]

Fifteen of 19 patients (79%) achieved objective responses (1 complete response and 14 partial responses), and the median duration of response was 18.4 months.

The most common grades 3 to 4 treatment-related adverse events were hypertension (12%), increased alanine aminotransferase (10%) and aspartate aminotransferase (7%), diarrhea (3%), and prolonged QT interval (2%).

In 2024, the FDA granted full approval to selpercatinib for the treatment of adult and pediatric patients aged 2 years and older with advanced or metastatic RET fusion–positive thyroid cancer who require systemic therapy and who are radioactive iodine–refractory (if radioactive iodine is appropriate).[60]

Sources: 60

Cabozantinib (a VEGFR and RET inhibitor). Cabozantinib and placebo were compared in a double-blind, phase III, randomized trial (COSMIC-311 [NCT03690388]) in adult patients (age range, 55–72 years). These patients had received at least one VEGFR-targeted TKI for differentiated thyroid carcinoma, and their disease was deemed progressive and radioactive iodine–refractory. An effective response was noted in 10 of 67 patients who received cabozantinib, compared with zero responses in the placebo group. The PFS was 11 months (95% CI, 7.4–13.8) in the cabozantinib arm, compared with 1.9 months (95% CI, 1.9–3.7) in the placebo arm, with an HR of 0.22 (95% CI, 0.14–0.31).[61] Based on these data, the FDA approved cabozantinib in this population.[62]

Sources: COSMIC-311 [NCT03690388] · 61 · 62

For more information, see Thyroid Cancer Treatment.

Sources: Thyroid Cancer Treatment

Health professional · Differentiated Thyroid Cancer (Papillary/Follicular) / Treatment of Recurrent Papillary and Follicular Thyroid Carcinoma

Treatment options under clinical evaluation for recurrent papillary and follicular thyroid carcinoma

Source: Childhood Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

Information about NCI-supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

Health professional · Medullary Thyroid Cancer

Treatment of Medullary Thyroid Carcinoma

Source: Childhood Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

Medullary thyroid carcinomas are commonly associated with the MEN2 syndrome. For more information, see Childhood Multiple Endocrine Neoplasia (MEN) Syndromes Treatment and Multiple Endocrine Neoplasia Type 2 (MEN2).

Sources: Childhood Multiple Endocrine Neoplasia (MEN) Syndromes Treatment · Multiple Endocrine Neoplasia Type 2 (MEN2)

Treatment options for medullary thyroid carcinoma include the following:

Surgery.

Sources: Surgery

Tyrosine kinase inhibitor (TKI) therapy.

Sources: Tyrosine kinase inhibitor (TKI) therapy

Health professional · Medullary Thyroid Cancer / Treatment of Medullary Thyroid Carcinoma

Surgery

Source: Childhood Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

Treatment for children with medullary thyroid carcinoma is mainly surgical. Investigators have concluded that prophylactic central node dissection should not be performed on patients with hereditary medullary thyroid cancer if their basal calcitonin serum levels are lower than 40 pg/mL.[15]

Sources: 15

Most cases of medullary thyroid carcinoma in children occur in the context of the MEN2A and MEN2B syndromes. In those familial cases, early genetic testing and counseling is indicated, and prophylactic surgery is recommended for children with the RET germline pathogenic variant. Strong genotype-phenotype correlations have facilitated the development of guidelines for intervention, including screening and age at which prophylactic thyroidectomy should occur.[11]

Sources: 11

Evidence (surgery):

A retrospective analysis identified 167 children with RET variants who underwent prophylactic thyroidectomy. This group included 109 patients without a concomitant central node dissection and 58 patients with a concomitant central node dissection. Postoperative hypoparathyroidism was more frequent in older children (32% in the oldest age group vs. 3% in the youngest age group; P = .002), regardless of whether central node dissection was carried out. Three children developed recurrent laryngeal nerve palsy after undergoing central node dissection (P = .040). All complications resolved within 6 months. Postoperative normalization of calcitonin serum levels was achieved in 114 of 115 children (99.1%) with raised preoperative values. Children were classified into risk groups by their specific type of RET variant (see Table 2).[16]

Sources: Table 2 · 16

A retrospective analysis identified 167 children with RET variants who underwent prophylactic thyroidectomy. This group included 109 patients without a concomitant central node dissection and 58 patients with a concomitant central node dissection. Postoperative hypoparathyroidism was more frequent in older children (32% in the oldest age group vs. 3% in the youngest age group; P = .002), regardless of whether central node dissection was carried out. Three children developed recurrent laryngeal nerve palsy after undergoing central node dissection (P = .040). All complications resolved within 6 months. Postoperative normalization of calcitonin serum levels was achieved in 114 of 115 children (99.1%) with raised preoperative values. Children were classified into risk groups by their specific type of RET variant (see Table 2).[16]

In the highest-risk category, medullary thyroid carcinoma was found in five of six children (83%) aged 3 years or younger.

In the high-risk category, medullary thyroid carcinoma was present in 6 of 20 children (30%) aged 3 years or younger, 16 of 36 children (44%) aged 4 to 6 years, and 11 of 16 children (69%) aged 7 to 12 years (P = .081).

In the moderate-risk category, medullary thyroid carcinoma was seen in one of nine children (11%) aged 3 years or younger, 1 of 26 children (4%) aged 4 to 6 years, 3 of 26 children (12%) aged 7 to 12 years, and 7 of 16 children (44%) aged 13 to 18 years (P = .006).

The American Thyroid Association has proposed the following guidelines for prophylactic thyroidectomy in children with hereditary medullary thyroid carcinoma (see Table 2).[11]

Sources: Table 2 · 11

Table 2. Risk Levels and Management Based on Common RET Variants Detected by Genetic Screeninga
Medullary Thyroid Carcinoma Risk Level
Highest (MEN2B)High (MEN2A)Moderate (MEN2A)
MEN2A = multiple endocrine neoplasia type 2A; MEN2B = multiple endocrine neoplasia type 2B.
aAdapted from Wells et al.[11]
RET VariantM918TA883F, C634F/G/R/S/W/YG533C, C609F/G/R/S/Y, C611F/G/S/Y/W, C618F/R/S, C620F/R/S, C630R/Y, D631Y, K666E, E768D, L790F, V804L, V804M, S891A, R912P
Age for Prophylactic ThyroidectomyTotal thyroidectomy in the first year of life, ideally in the first months of life.Total thyroidectomy at or before age 5 y based on serum calcitonin level.Total thyroidectomy to be performed when the serum calcitonin level is above the normal range or at convenience if the parents do not wish to embark on a lengthy period of surveillance.

Sources: 11

Health professional · Medullary Thyroid Cancer / Treatment of Medullary Thyroid Carcinoma

Tyrosine kinase inhibitor (TKI) therapy

Source: Childhood Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

A number of TKIs have been evaluated and approved for patients with advanced medullary thyroid carcinoma.

Vandetanib. Vandetanib is an inhibitor of the RET kinase, VEGFR, and EGFR signaling. The U.S. Food and Drug Administration (FDA) approved vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in adult patients with unresectable, locally advanced, or metastatic disease. The approval was based on a randomized, placebo-controlled, phase III trial that showed a marked progression-free survival (PFS) improvement for patients randomly assigned to receive vandetanib (hazard ratio, 0.35). The trial also showed an objective response rate advantage for patients receiving vandetanib (44% vs. 1% for the placebo arm).[17,18]Children with locally advanced or metastatic medullary thyroid carcinoma were treated with vandetanib in a phase I/II trial. Of 16 patients, only 1 had no response, and 7 had partial responses, for an objective response rate of 44%. Disease in three of those patients subsequently recurred, but 11 of 16 patients treated with vandetanib remained on therapy at the time of the report. The median duration of therapy for the entire cohort was 27 months, with a range of 2 to 52 months.[19] A long-term outcome evaluation in a cohort of 17 children and adolescents with advanced medullary thyroid carcinoma who received vandetanib reported a median PFS of 6.7 years and a 5-year OS rate of 88.2%.[20]

Sources: 17 · 18 · 19 · 20

Cabozantinib. Cabozantinib is an inhibitor of the RET and MET kinases and VEGFR. It has also shown activity against unresectable medullary thyroid cancer (10 of 35 adult patients [29%] had partial responses).[21] A double-blind phase III trial compared cabozantinib with placebo in adults with progressive, metastatic medullary thyroid carcinoma.[22] The estimated PFS was 11.2 months for patients who received cabozantinib and 4 months for patients who received the placebo. At 1 year, 47.3% of patients who were treated with cabozantinib were alive and progression free, compared with 7.2% of patients who received the placebo. Significant adverse effects resulted in dose reductions in 79% of patients and discontinuation of cabozantinib in 16% of patients. The FDA approved cabozantinib in 2012 for the treatment of adults with metastatic medullary thyroid cancer.

Sources: 21 · 22

Selpercatinib. Selpercatinib is a RET inhibitor. A phase I/II trial of selpercatinib therapy for patients with RET-altered cancers enrolled 55 patients with medullary thyroid cancer (age range, 17–84 years) who were previously treated with vandetanib and/or cabozantinib and 88 patients with medullary thyroid cancer (age range, 15–82 years) who were not previously treated with vandetanib or cabozantinib.[23]

Sources: 23

Selpercatinib. Selpercatinib is a RET inhibitor. A phase I/II trial of selpercatinib therapy for patients with RET-altered cancers enrolled 55 patients with medullary thyroid cancer (age range, 17–84 years) who were previously treated with vandetanib and/or cabozantinib and 88 patients with medullary thyroid cancer (age range, 15–82 years) who were not previously treated with vandetanib or cabozantinib.[23]

For the previously treated cohort, 69% of patients had objective responses, and the median duration of response had not been reached, with a median follow-up of 14 months.

For the cohort of patients who were not previously treated, 73% of patients had objective responses, with a median duration of response of 22 months.

The most common grades 3 to 4 treatment-related adverse events were hypertension (12%), increased alanine aminotransferase (10%) and aspartate aminotransferase (7%), diarrhea (3%), and prolonged QT interval (2%).

In a small cohort of six children with recurrent medullary thyroid carcinoma who were treated with selpercatinib, all patients had ongoing responses at a median follow-up of 13 months.[24]

Sources: 24

In 2024, the FDA granted full approval to selpercatinib for the treatment of adult and pediatric patients aged 2 years and older with advanced or metastatic RET fusion–positive medullary thyroid cancer who require systemic therapy.[25]

Sources: 25

For more information, see Childhood Multiple Endocrine Neoplasia (MEN) Syndromes Treatment and Multiple Endocrine Neoplasia Type 2 (MEN2).

Sources: Childhood Multiple Endocrine Neoplasia (MEN) Syndromes Treatment · Multiple Endocrine Neoplasia Type 2 (MEN2)

Health professional · Medullary Thyroid Cancer / Treatment of Medullary Thyroid Carcinoma

Treatment options under clinical evaluation for medullary thyroid carcinoma

Source: Childhood Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

Health professional

Special Considerations for the Treatment of Children With Cancer

Source: Childhood Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence. This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:

Sources: 1

Primary care physicians.

Pediatric surgeons.

Pathologists.

Pediatric radiation oncologists.

Pediatric medical oncologists and hematologists.

Ophthalmologists.

Rehabilitation specialists.

Pediatric oncology nurses.

Social workers.

Child-life professionals.

Psychologists.

Nutritionists.

For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.

Sources: Supportive and Palliative Care

The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[2] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.

Sources: 2 · NCI website

Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2020, childhood cancer mortality decreased by more than 50%.[3-5] Childhood and adolescent cancer survivors require close monitoring because side effects of cancer therapy may persist or develop months or years after treatment. For information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see Late Effects of Treatment for Childhood Cancer.

Sources: 3 · 5 · Late Effects of Treatment for Childhood Cancer

Childhood cancer is a rare disease, with about 15,000 cases diagnosed annually in the United States in individuals younger than 20 years.[6] The U.S. Rare Diseases Act of 2002 defines a rare disease as one that affects populations smaller than 200,000 people in the United States. Therefore, all pediatric cancers are considered rare.

Sources: 6 · Rare Diseases Act of 2002

The designation of a rare tumor is not uniform among pediatric and adult groups. In adults, rare cancers are defined as those with an annual incidence of fewer than six cases per 100,000 people. They account for up to 24% of all cancers diagnosed in the European Union and about 20% of all cancers diagnosed in the United States.[7,8] In children and adolescents, the designation of a rare tumor is not uniform among international groups, as follows:

Sources: 7 · 8

A consensus effort between the European Union Joint Action on Rare Cancers and the European Cooperative Study Group for Rare Pediatric Cancers estimated that 11% of all cancers in patients younger than 20 years could be categorized as very rare. This consensus group defined very rare cancers as those with annual incidences of fewer than two cases per 1 million people. However, three additional histologies (thyroid carcinoma, melanoma, and testicular cancer) with incidences of more than two cases per 1 million people were also included in the very rare group due to a lack of knowledge and expertise in the management of these tumors.[9]

Sources: 9

The Children's Oncology Group defines rare pediatric cancers as those listed in the International Classification of Childhood Cancer subgroup XI, which includes thyroid cancers, melanomas and nonmelanoma skin cancers, and multiple types of carcinomas (e.g., adrenocortical carcinomas, nasopharyngeal carcinomas, and most adult-type carcinomas such as breast cancers and colorectal cancers).[10] These diagnoses account for about 5% of the cancers diagnosed in children aged 0 to 14 years and about 27% of the cancers diagnosed in adolescents aged 15 to 19 years.[4] Most cancers in subgroup XI are either melanomas or thyroid cancers, with other cancer types accounting for only 2% of the cancers diagnosed in children aged 0 to 14 years and 9.3% of the cancers diagnosed in adolescents aged 15 to 19 years.

Sources: 10 · 4

These rare cancers are extremely challenging to study because of the relatively few patients with any individual diagnosis, the predominance of rare cancers in the adolescent population, and the small number of clinical trials for adolescents with rare cancers.

Information about these tumors may also be found in sources relevant to adults with cancer, such as Thyroid Cancer Treatment.

Sources: Thyroid Cancer Treatment

For patients

Types of treatment for childhood thyroid cancer

Source: Childhood Thyroid Cancer (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 16, 2024. Captured 2026-09-09.

For patients · Types of treatment for childhood thyroid cancer

Who treats children with thyroid cancer?

Source: Childhood Thyroid Cancer (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 16, 2024. Captured 2026-09-09.

A pediatric oncologist, a doctor who specializes in treating children with cancer, oversees treatment of thyroid cancer. The pediatric oncologist works with other health care providers who are experts in treating children with cancer and who specialize in certain areas of medicine. Other specialists may include:

pediatrician

Sources: pediatrician

pediatric surgeon

Sources: pediatric surgeon

radiation oncologist

Sources: radiation oncologist

pathologist

pediatric nurse specialist

Sources: pediatric nurse specialist

social worker

Sources: social worker

rehabilitation specialist

Sources: rehabilitation specialist

psychologist

Sources: psychologist

child-life specialist

Sources: child-life specialist

There are different types of treatment for children and adolescents with thyroid cancer. You and your child's cancer care team will work together to decide treatment. Many factors will be considered, such as your child's overall health and whether the tumor is newly diagnosed or has come back.

Your child's treatment plan will include information about the cancer, the goals of treatment, treatment options, and the possible side effects. It will be helpful to talk with your child's cancer care team before treatment begins about what to expect. For help every step of the way, see our booklet, Children with Cancer: A Guide for Parents.

Sources: Children with Cancer: A Guide for Parents

Treatment for thyroid cancer might include:

For patients · Types of treatment for childhood thyroid cancer

Surgery

Source: Childhood Thyroid Cancer (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 16, 2024. Captured 2026-09-09.

Surgery is the most common treatment for thyroid cancer. One of the following procedures may be used:

Total thyroidectomy is the removal of the whole thyroid. Lymph nodes near the cancer may also be removed and checked under a microscope for signs of cancer.

Near-total thyroidectomy is the removal of all but a very small part of the thyroid. Lymph nodes near the cancer may also be removed and checked under a microscope for signs of cancer.

In children, a total thyroidectomy is usually done.

Learn more about Surgery to Treat Cancer.

Sources: Surgery to Treat Cancer

For patients · Types of treatment for childhood thyroid cancer

Radioactive iodine therapy

Source: Childhood Thyroid Cancer (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 16, 2024. Captured 2026-09-09.

Follicular and papillary thyroid cancers are sometimes treated with radioactive iodine (RAI) therapy. RAI therapy may be given to children after surgery to kill any thyroid cancer cells that were not removed or to children whose tumor cannot be removed by surgery. RAI is taken by mouth and collects in any remaining thyroid tissue, including thyroid cancer cells that have spread to other places in the body. Because only thyroid tissue takes up iodine, the RAI destroys thyroid tissue and thyroid cancer cells without harming other tissue. Before a full treatment dose of RAI is given, a small test dose is given to see if the tumor takes up the iodine.

For patients · Types of treatment for childhood thyroid cancer

Targeted therapy

Source: Childhood Thyroid Cancer (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 16, 2024. Captured 2026-09-09.

Targeted therapy uses drugs or other substances to block the action of specific enzymes, proteins, and other molecules involved in the growth and spread of cancer cells. Targeted therapies used to treat thyroid cancer include:

Sources: enzymes · molecules

entrectinib

Sources: entrectinib

larotrectinib

Sources: larotrectinib

selpercatinib

Sources: selpercatinib

vandetanib

Sources: vandetanib

Learn more about Targeted Therapy to Treat Cancer.

Sources: Targeted Therapy to Treat Cancer

For patients · Types of treatment for childhood thyroid cancer

Clinical trials

Source: Childhood Thyroid Cancer (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 16, 2024. Captured 2026-09-09.

Joining a clinical trial may be an option. There are different types of clinical trials for childhood cancer. For example, a treatment trial tests new treatments or new ways of using existing treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.

You can use the clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. The search allows you to filter trials based on the type of cancer, your child's age, and where the trials are being done.

Sources: clinical trial search

Learn more at Clinical Trials Information for Patients and Caregivers.

Sources: Clinical Trials Information for Patients and Caregivers

For patients · Types of treatment for childhood thyroid cancer

Treatment of newly diagnosed childhood papillary and follicular thyroid cancer

Source: Childhood Thyroid Cancer (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 16, 2024. Captured 2026-09-09.

Treatment of papillary and follicular thyroid carcinoma in children may include:

Surgery to remove all or most of the thyroid gland and sometimes lymph nodes near the thyroid gland. Radioactive iodine therapy may also be given if any thyroid cancer cells remain after surgery. Hormone replacement therapy (HRT) is given to make up for the lost thyroid hormone.

Sources: Hormone replacement therapy · thyroid hormone

Radioactive iodine therapy alone may be given to children whose tumor cannot be removed by surgery. HRT is given to make up for the lost thyroid hormone.

For patients · Types of treatment for childhood thyroid cancer

Treatment of newly diagnosed childhood medullary thyroid cancer

Source: Childhood Thyroid Cancer (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 16, 2024. Captured 2026-09-09.

Treatment of medullary thyroid cancer in children may include:

surgery to remove the cancer

targeted therapy (selpercatinib or vandetanib) for cancer that has continued to grow during treatment or has spread to other parts of the body

For patients · Types of treatment for childhood thyroid cancer

Treatment of progressive or recurrent childhood thyroid cancer

Source: Childhood Thyroid Cancer (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 16, 2024. Captured 2026-09-09.

Treatment of progressive or recurrent papillary and follicular thyroid carcinoma in children may include:

Sources: progressive · recurrent

radioactive iodine therapy

targeted therapy (entrectinib, larotrectinib, or selpercatinib)

If the cancer comes back after treatment, your child's doctor will talk with you about what to expect and possible next steps. There might be treatment options that may shrink the cancer or control its growth. If there are no treatments, your child can receive care to control symptoms from cancer so they can be as comfortable as possible.

For patients

Side effects and late effects of treatment

Source: Childhood Thyroid Cancer (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 16, 2024. Captured 2026-09-09.

Cancer treatments can cause side effects. Which side effects your child might have depends on the type of treatment they receive, the dose, and how their body reacts. Talk with your child's treatment team about which side effects to look for and ways to manage them.

To learn more about side effects that begin during treatment for cancer, visit Side Effects.

Sources: side effects · Side Effects

Problems from cancer treatment that begin 6 months or later after treatment and continue for months or years are called late effects. Late effects of cancer treatment for childhood thyroid cancer may include:

changes in the salivary glands

Sources: salivary glands

increased risk of infection

Sources: infection

trouble breathing

changes in mood, feelings, thinking, learning, or memory

second cancers (new types of cancer)

Some late effects may be treated or controlled. It is important to talk with your child's doctors about the effects cancer treatment can have on your child. Learn more about Late Effects of Treatment for Childhood Cancer.

Sources: Late Effects of Treatment for Childhood Cancer

Studies

Natural History Study of Children and Adults With Medullary Thyroid Cancer

NCT01660984 · ACTIVE NOT RECRUITING · Phase not reported

Medullary Thyroid Cancer

ClinicalTrials.gov record

Disease and treatment settings

CABOMETYX: metastatic Thyroid Cancer after prior therapy

Disease and treatment setting

1.3 Differentiated Thyroid Cancer CABOMETYX is indicated for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following...

Childhood Thyroid Cancer

Disease and treatment setting

Thyroid Cancer in children and adolescents

Childhood Thyroid Cancer

Disease and treatment setting

Treatment of newly diagnosed childhood papillary and follicular thyroid cancer

Gavreto: metastatic Thyroid Cancer with RET fusion

Disease and treatment setting

Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)

Gavreto: metastatic Thyroid Cancer with RET Fusion, RET fusion

Disease and treatment setting

1.2 RET Fusion-Positive Thyroid Cancer GAVRETO is indicated for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who...

Gavreto: metastatic Thyroid Cancer with RET mutant

Disease and treatment setting

Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy

recurrent Childhood Thyroid Cancer

Disease and treatment setting

Treatment of Recurrent Papillary and Follicular Thyroid Carcinoma

Retevmo: metastatic Thyroid Cancer with RET fusion

Disease and treatment setting

Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) *

RETEVMO: metastatic Thyroid Cancer with RET Fusion, RET stated without a specific alteration

Disease and treatment setting

1.3 RET Fusion-Positive Thyroid Cancer RETEVMO is indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved...

Retevmo: metastatic Thyroid Cancer with RET mutant

Disease and treatment setting

Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy *

RETEVMO: metastatic Thyroid Cancer with RET mutation

Disease and treatment setting

Adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy ( 1.2 )

RETEVMO: metastatic Thyroid Cancer with RET stated without a specific alteration

Disease and treatment setting

Adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if...

RETEVMO: metastatic Thyroid Cancer with RET stated without a specific alteration, RET mutation

Disease and treatment setting

1.2 RET -Mutant Medullary Thyroid Cancer RETEVMO is indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an...